These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 28746788)

  • 1. A randomized placebo-controlled trial of prophylactic dexamethasone for transcatheter arterial chemoembolization.
    Ogasawara S; Chiba T; Ooka Y; Kanogawa N; Motoyama T; Suzuki E; Tawada A; Nagai K; Nakagawa T; Sugawara T; Hanaoka H; Kanai F; Yokosuka O
    Hepatology; 2018 Feb; 67(2):575-585. PubMed ID: 28746788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dexamethasone Prophylaxis to Alleviate Postembolization Syndrome after Transarterial Chemoembolization for Hepatocellular Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled Study.
    Yang H; Seon J; Sung PS; Oh JS; Lee HL; Jang B; Chun HJ; Jang JW; Bae SH; Choi JY; Yoon SK
    J Vasc Interv Radiol; 2017 Nov; 28(11):1503-1511.e2. PubMed ID: 28941589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of palonosetron and dexamethasone administration on the prevention of gastrointestinal symptoms in hepatic arterial chemoembolization with epirubicin.
    Sakamoto T; Saito Y; Kobayashi M; Yamada T; Takekuma Y; Nakai M; Ogawa K; Iseki K; Sugawara M
    Support Care Cancer; 2020 Jul; 28(7):3251-3257. PubMed ID: 31732854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single dose dexamethasone prophylaxis of postembolisation syndrome after chemoembolisation in hepatocellular carcinoma patient: A randomised, double-blind, placebo-controlled study.
    Sainamthip P; Kongphanich C; Prasongsook N; Chirapongsathorn S
    World J Clin Cases; 2021 Oct; 9(30):9059-9069. PubMed ID: 34786388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Ginsenosides combined with dexamethasone in preventing and treating postembolization syndrome following transcatheter arterial chemoembolization: a randomized, controlled and double-blinded prospective trial].
    Feng YL; Ling CQ; Zhu DZ; Yu CQ; Chen Z; Li B
    Zhong Xi Yi Jie He Xue Bao; 2005 Mar; 3(2):99-102. PubMed ID: 15763053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How to prophylactically alleviate postembolization syndrome following transarterial chemoembolization?: Protocol of a double blinded, randomized, placebo-controlled trial.
    Pan Y; Chang R; He Z; Hong M
    Medicine (Baltimore); 2021 Apr; 100(14):e25360. PubMed ID: 33832116
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nausea and vomiting after transcatheter arterial chemoembolization for hepatocellular carcinoma: incidence and risk factor analysis.
    Wang SY; Zhu WH; Vargulick S; Lin SB; Meng ZQ
    Asian Pac J Cancer Prev; 2013; 14(10):5995-6000. PubMed ID: 24289614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial.
    Saito M; Aogi K; Sekine I; Yoshizawa H; Yanagita Y; Sakai H; Inoue K; Kitagawa C; Ogura T; Mitsuhashi S
    Lancet Oncol; 2009 Feb; 10(2):115-24. PubMed ID: 19135415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A double-blind crossover study comparing prophylactic intravenous granisetron alone or in combination with dexamethasone as antiemetic treatment in controlling nausea and vomiting associated with chemotherapy.
    Kirchner V; Aapro M; Terrey JP; Alberto P
    Eur J Cancer; 1997 Sep; 33(10):1605-10. PubMed ID: 9389922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical study on integrative medicine for preventing and treating post-transcatheter arterial chemoembolization].
    Feng YL; Ling CQ; Li B
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2005 Jun; 25(6):534-6. PubMed ID: 16025970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatocellular Carcinoma: A Phase II Randomized Controlled Double-Blind Trial of Transarterial Chemoembolization in Combination with Biweekly Intravenous Administration of Bevacizumab or a Placebo.
    Pinter M; Ulbrich G; Sieghart W; Kölblinger C; Reiberger T; Li S; Ferlitsch A; Müller C; Lammer J; Peck-Radosavljevic M
    Radiology; 2015 Dec; 277(3):903-12. PubMed ID: 26131911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of transcutaneous electrical acupoint stimulation combined with palonosetron on chemotherapy-induced nausea and vomiting: a single-blind, randomized, controlled trial.
    Xie J; Chen LH; Ning ZY; Zhang CY; Chen H; Chen Z; Meng ZQ; Zhu XY
    Chin J Cancer; 2017 Jan; 36(1):6. PubMed ID: 28069044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial.
    Grunberg SM; Rolski J; Strausz J; Aziz Z; Lane S; Russo MW; Wissel P; Guckert M; Wright O; Herrstedt J
    Lancet Oncol; 2009 Jun; 10(6):549-58. PubMed ID: 19428297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of transcatheter arterial chemoembolization combined with ginsenosides in hepatocellular carcinoma treatment.
    Zhu H; Wang SY; Zhu JH; Liu H; Kong M; Mao Q; Zhang W; Li SL
    Phytomedicine; 2021 Oct; 91():153700. PubMed ID: 34425474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized double-blind trial of ondansetron alone versus in combination with dexamethasone versus in combination with dexamethasone and lorazepam in the prevention of emesis due to cisplatin-based chemotherapy.
    Ahn MJ; Lee JS; Lee KH; Suh C; Choi SS; Kim SH
    Am J Clin Oncol; 1994 Apr; 17(2):150-6. PubMed ID: 8141107
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aprepitant, granisetron, and dexamethasone for prevention of chemotherapy-induced nausea and vomiting after high-dose melphalan in autologous transplantation for multiple myeloma: results of a randomized, placebo-controlled phase III trial.
    Schmitt T; Goldschmidt H; Neben K; Freiberger A; Hüsing J; Gronkowski M; Thalheimer M; Pelzl le H; Mikus G; Burhenne J; Ho AD; Egerer G
    J Clin Oncol; 2014 Oct; 32(30):3413-20. PubMed ID: 25225424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new way: alleviating postembolization syndrome following transcatheter arterial chemoembolization.
    Yinglu F; Changquan L; Xiaofeng Z; Bai L; Dezeng Z; Zhe C
    J Altern Complement Med; 2009 Feb; 15(2):175-81. PubMed ID: 19216654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting.
    Chawla SP; Grunberg SM; Gralla RJ; Hesketh PJ; Rittenberg C; Elmer ME; Schmidt C; Taylor A; Carides AD; Evans JK; Horgan KJ
    Cancer; 2003 May; 97(9):2290-300. PubMed ID: 12712486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of dexamethasone and N-acetylcysteine combination in preventing post-embolization syndrome after transarterial chemoembolization in hepatocellular carcinoma.
    Simasingha N; Tanasoontrarat W; Claimon T; Sethasine S
    World J Gastroenterol; 2023 Feb; 29(5):890-903. PubMed ID: 36816622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, double-blind, parallel, comparative study to evaluate the efficacy and safety of ramosetron plus dexamethasone injection for the prevention of acute chemotherapy-induced nausea and vomiting.
    Ho CL; Su WC; Hsieh RK; Lin ZZ; Chao TY
    Jpn J Clin Oncol; 2010 Apr; 40(4):294-301. PubMed ID: 20026457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.